# OnCo record nct07393282 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07393282/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07393282", "NCT07393282" ;
  schema:name "A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)"@en ;
  schema:alternateName "LINKER-SMM2"@en ;
  schema:description "A phase 3 trial of Linvoseltamab, Daratumumab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07393282/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07393282> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-05-21" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/smouldering-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> .